Lee Silverman voice treatment versus standard NHS speech and language therapy versus control in Parkinson’s disease PD COMM pilot: study protocol for a randomized controlled trialReportar como inadecuado

Lee Silverman voice treatment versus standard NHS speech and language therapy versus control in Parkinson’s disease PD COMM pilot: study protocol for a randomized controlled trial - Descarga este documento en PDF. Documentación en PDF para descargar gratis. Disponible también para leer online.


, 15:213

First Online: 07 June 2014Received: 17 February 2014Accepted: 20 May 2014DOI: 10.1186-1745-6215-15-213

Cite this article as: Sackley, C.M., Smith, C.H., Rick, C. et al. Trials 2014 15: 213. doi:10.1186-1745-6215-15-213


BackgroundParkinson’s disease is a common movement disorder affecting approximately 127,000 people in the UK, with an estimated two thirds having speech-related problems. Currently there is no preferred approach to speech and language therapy within the NHS and there is little evidence for the effectiveness of standard NHS therapy or Lee Silverman voice treatment. This trial aims to investigate the feasibility and acceptability of randomizing people with Parkinson’s disease-related speech or voice problems to Lee Silverman voice treatment or standard speech and language therapy compared to a no-intervention control.

Methods-DesignThe PD COMM pilot is a three arm, assessor-blinded, randomized controlled trial. Randomization will be computer-generated with participants randomized at a ratio of 1:1:1. Participants randomized to intervention arms will be immediately referred to the appropriate speech and language therapist. The target population are patients with a confirmed diagnosis of idiopathic Parkinson’s disease who have problems with their speech or voice. The Lee Silverman voice treatment intervention group will receive the standard regime of 16 sessions between 50 and 60 minutes in length over four weeks, with extra home practice. The standard speech and language therapy intervention group will receive a dose determined by patients’ individual needs, but not exceeding eight weeks of treatment. The control group will receive standard care with no speech and language therapy input for at least six months post-randomization. Outcomes will be assessed at baseline pre-randomization and post- randomization at three, six, and 12 months. The outcome measures include patient-reported voice measures, quality of life, resource use, and assessor-rated speech recordings. The recruitment aim is at least 60 participants over 21 months from 11 sites, equating to at least 20 participants in each arm of the trial. This trial is ongoing and recruitment commenced in May 2012.

DiscussionThis study will provide information on the feasibility and acceptability of randomizing participants to different speech and language therapies or control-deferred treatment. The findings relating to recruitment, treatment compliance, outcome measures, and effect size will inform a future phase III randomized controlled trial.

Trial registrationInternational Standard Randomised Controlled Trial Number Register: ISRCTN75223808 registered 22 March 2012.

KeywordsParkinson’s disease Speech and language therapy Lee Silverman Voice Treatment Randomized controlled trial LSVT® AbbreviationsAACAugmentative and Alternative Communication

AIDSAssessment of intelligibility of dysarthric speech

EQ-5DEuroQol 5 Dimensions

ICECAP-OICEpop CAPability measure for Older people

LSVT®Lee Silverman Voice Treatment

LwDLiving with Dysarthria questionnaire

NHSNational Health Service

PDParkinson’s Disease

PDQ-39Parkinson’s Disease Questionnaire

RCTRandomized Controlled Trial

SLTSpeech and Language Therapy

SOPSStandard Operating Procedures

VHIVoice Handicap Index

V-RQOLVoice-Related QoL scale.

Electronic supplementary materialThe online version of this article doi:10.1186-1745-6215-15-213 contains supplementary material, which is available to authorized users.

Download fulltext PDF

Autor: Catherine M Sackley - Christina H Smith - Caroline Rick - Marian C Brady - Natalie Ives - Ramilla Patel - Helen Roberts

Fuente: https://link.springer.com/

Documentos relacionados